BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 7738623)

  • 1. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
    Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
    J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
    Loehrer PJ; Ansari R; Gonin R; Monaco F; Fisher W; Sandler A; Einhorn LH
    J Clin Oncol; 1995 Oct; 13(10):2594-9. PubMed ID: 7595712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
    Einhorn LH; Loehrer PJ
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):28-31. PubMed ID: 7846539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
    Hanna NH; Sandier AB; Loehrer PJ; Ansari R; Jung SH; Lane K; Einhorn LH
    Ann Oncol; 2002 Jan; 13(1):95-102. PubMed ID: 11863118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
    Einhorn LH; Pennington K; McClean J
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):32-5. PubMed ID: 2154857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
    Glisson B; Scott C; Komaki R; Movsas B; Wagner H
    J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
    Woo IS; Park YS; Kwon SH; Park YL; Lee JA; Park MJ; Hyun IG; Jung KS; Bae HS; Oh DH; Kim WS; Park K; Park CH; Kim HJ; Ahn YC
    Jpn J Clin Oncol; 2000 Dec; 30(12):542-6. PubMed ID: 11210163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.